Your browser is no longer supported. Please, upgrade your browser.
Settings
RVPH [NASD]
Reviva Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own27.40% Shs Outstand9.23M Perf Week-12.15%
Market Cap38.98M Forward P/E- EPS next Y-1.72 Insider Trans0.00% Shs Float5.23M Perf Month-44.74%
Income-0.70M PEG- EPS next Q-0.06 Inst Own3.90% Short Float0.21% Perf Quarter-52.61%
Sales- P/S- EPS this Y-15.90% Inst Trans-89.45% Short Ratio0.32 Perf Half Y-59.05%
Book/sh10.97 P/B0.40 EPS next Y-38.70% ROA-1.40% Target Price- Perf Year-57.39%
Cash/sh0.00 P/C- EPS next 5Y- ROE-1.50% 52W Range3.93 - 15.10 Perf YTD-49.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.79% Beta-
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low12.21% ATR0.50
Employees5 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)26.07 Volatility8.15% 10.02%
OptionableNo Debt/Eq0.05 EPS Q/Q-278.70% Profit Margin- Rel Volume0.76 Prev Close4.22
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume34.43K Price4.41
Recom- SMA20-21.64% SMA50-40.62% SMA200-53.88% Volume26,216 Change4.50%
Apr-14-21 06:23AM  
Apr-01-21 11:45AM  
Mar-22-21 08:26AM  
Mar-11-21 05:36PM  
Mar-04-21 05:00PM  
Jan-19-21 04:40AM  
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.